Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2018

At a glance

  • Drugs VX 150 (Primary)
  • Indications Pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 18 Dec 2018 Primary endpoint has been met. (Change from baseline in the weekly average of daily pain intensity on the 11 point numeric rating scale (NRS), as reported in the daily diary), according to a Vertex Pharmaceuticals media release.
    • 18 Dec 2018 Results presented in a Vertex Pharmaceuticals media release.
    • 07 Dec 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top